Bictegravir-Tenofovir alafenamide-Emtricitabine Biktarvy
Darunavir-Cobicistat-Tenofovir alafenamide-Emtricitabine Symtuza
Dolutegravir-Abacavir-Lamivudine Triumeq
Dolutegravir-Lamivudine Dovato
Dolutegravir-Rilpivirine Juluca
Doravirine-Tenofovir DF-Lamivudine Delstrigo
Efavirenz-Tenofovir DF-Emtricitabine Atripla
Elvitegravir-Cobicistat-Tenofovir alafenamide-Emtricitabine Genvoya
Elvitegravir-Cobicistat-Tenofovir DF-Emtricitabine Stribild
Rilpivirine-Tenofovir alafenamide-Emtricitabine Odefsey
Rilpivirine-Tenofovir DF-Emtricitabine Complera
Enfuvirtide Fuzeon
Fostemsavir Rukobia
Ibalizumab Trogarzo
Maraviroc Selzentry
Dolutegravir Tivicay
Raltegravir Isentress
Abacavir Ziagen
Abacavir-Lamivudine Epzicom
Abacavir-Lamivudine-Zidovudine Trizivir
Didanosine Videx
Emtricitabine Emtriva
Lamivudine Epivir
Stavudine Zerit
Tenofovir alafenamide-Emtricitabine Descovy
Tenofovir DF Viread
Tenofovir DF-Emtricitabine Truvada and Multiple Generics
Zidovudine Retrovir
Zidovudine-Lamivudine Combivir
Doravirine Pifeltro
Efavirenz Sustiva
Etravirine Intelence
Nevirapine Viramune
Rilpivirine Edurant
Atazanavir Reyataz
Atazanavir-Cobicistat Evotaz
Darunavir Prezista
Darunavir-Cobicistat Prezcobix
Fosamprenavir Lexiva
Indinavir Crixivan
Lopinavir-Ritonavir Kaletra
Nelfinavir Viracept
Saquinavir Invirase
Tipranavir Aptivus
Cobicistat Tybost
Ritonavir NorvirSection Navigation
Section Navigation
- Module 4 Overview
Co-Occurring Conditions - 0%Lesson 1
Latent Tuberculosis InfectionActivities- 0%Lesson 2
Opportunistic Infections: PreventionActivities- 0%Lesson 3
Opportunistic Infections: TreatmentActivities- 0%Lesson 4
Sexually Transmitted InfectionsActivities- 0%Lesson 5
Hepatitis B CoinfectionLesson 5. Hepatitis B Coinfection
Learning Objective Performance Indicators
- Identify appropriate tests for evaluation of hepatitis B virus (HBV) infection and immunity
- Summarize the approach to persons with HIV who have isolated hepatitis B core antibody
- Discuss antiretroviral management of persons with HIV and HBV coinfection
- Describe HBV-related immune reconstitution syndrome
- List indications and methods for hepatocellular carcinoma surveillance in persons with chronic HBV and HIV coinfection
About this Lesson
Learning Objective Performance Indicators
- Identify appropriate tests for evaluation of hepatitis B virus (HBV) infection and immunity
- Summarize the approach to persons with HIV who have isolated hepatitis B core antibody
- Discuss antiretroviral management of persons with HIV and HBV coinfection
- Describe HBV-related immune reconstitution syndrome
- List indications and methods for hepatocellular carcinoma surveillance in persons with chronic HBV and HIV coinfection
Activities in this Lesson
- Quick ReferenceHepatitis B Coinfection Core Concepts
- Background
- Screening for HBV in Persons with HIV
- Initial Evaluation of Persons with HBV and HIV Coinfection
- Treatment of HBV and HIV in Persons with HIV and HBV Coinfection
- Monitoring HBV Treatment Response
- Management of HIV or HBV Virologic Failure
- Stopping HBV Treatment and Hepatic Flares
- HBV-Related Immune Reconstitution Syndrome (HBV-IRIS)
- Hepatitis D Virus
- Preventing HBV Perinatal Transmission
- Surveillance for Hepatocellular Carcinoma
- Managing Persons with Coinfection and Advanced Liver Disease
- Summary Points
- Activity 5B.Hepatitis Delta Infection
Share by e-mail
Check
-On-
Learning
QuestionsThe Check-on-Learning Questions are short and topic related. They are meant to help you stay on track throughout each lesson and check your understanding of key concepts.You must be signed in to customize your interaction with these questions.
- 0%Lesson 2
Funded by
Health Resources and Services Administration (HRSA)
Created at
University of Washington
An AETC Program
Part of
IDEA Platform
CME provided byUniversity of Alabama Birmingham
CNE provided byUniversity of Washington School of Nursing
Copyright © 2024 National HIV Curriculum
The National HIV Curriculum is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of a financial assistance award totaling $1,172,990 with 0% financed with non-governmental sources. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by HRSA, HHS, or the U.S. Government. For more information, please visit HRSA.gov
Since you've received 80% or better on this quiz, you may claim continuing education credit.
You seem to have a popup blocker enabled. If you want to skip this dialog please Always allow popup windows for the online course.
Current Version: nhivc-master-6c628bd7-2024-12-09-232956